Baxter International, Inc.
One Baxter Parkway
About Baxter International, Inc.
Baxter touches millions of lives every day. Our products and services are essential building blocks of healthcare.
You’ll find Baxter’s products and therapies on nearly every floor, in every department, in almost every hospital worldwide. You’ll find us in clinics and in the home. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Our mission to save and sustain lives inspires our work and our commitment to expanding access to care, providing cost-effective healthcare solutions, delivering quality products and advancing innovations for the world.
Our commitment to our mission means we are there when patients and healthcare professionals need us, during the critical moments that matter most.
CEO: José (Joe) E. Almeida
CMO: James R. Gavin III
CTO: Uma Chowdhry
CFO: Peter Hellman
Please click here for Baxter job opportunities.
FOLLOW BAXTER INTERNATIONAL:
Tweets by Baxer International
719 articles with Baxter International, Inc.
The medical device market was about $521.2 billion last year and is projected to hit $674.5 billion by 2022. Here’s a look at the top 10 medical device companies in the world this year.
Baxter Unveiled Updates to SHARESOURCE Remote Patient Management Platform for Home Dialysis Patients at ERA-EDTA 2018
Baxter International Inc. announced the availability of two program updates for its SHARESOURCE remote patient management platform to support greater accessibility and efficiencies in remotely viewing patient data.
Baxter Supported Nine New Abstract Presentations at the 55th ERA-EDTA Congress That Further Demonstrate Value of HDx Therapy Enabled by THERANOVA
Baxter International Inc. announced new data reinforcing that expanded hemodialysis (HDx) enabled by the THERANOVA dialyzer.
Company Increases Financial Guidance for 2020 and Provides Outlook for 2023
Designed with Exclusive New Features for Bi-Directional Electronic Medical Records Integration Including Auto-Programming and Auto-Documentation
Baxter and the International Society of Nephrology Announce a Collaboration to Address Growing Prevalence of Kidney Disease
Baxter International Inc. announced a partnership to advance chronic kidney disease (CKD) awareness and help improve access to therapy, particularly in low- and middle-income countries (LMIC) – commonly referenced as emerging markets – where the disease prevalence is growing the fastest.
First-Quarter Revenue of $2.7 Billion Increased 8 Percent on a Reported Basis and 3 Percent on an Operational Basis
Baxter International, Inc. will host a conference call to discuss its first quarter 2018 financial results on Thursday, April 26, 2018, at 7:30 a.m. Central Daylight Time.
Baxter International, Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.
Shire stock prices jumped up to 26 percent on rumors that Takeda Pharmaceuticals was considering a buyout.
Baxter Completes Acquisition of RECOTHROM and PREVELEAK to Broaden Surgical Hemostat and Sealant Portfolio
RECOTHROM Thrombin topical (Recombinant) is the first and only stand-alone recombinant thrombin and PREVELEAK Surgical Sealant is used in vascular reconstruction.
Baxter International Inc. (NYSE:BAX) today announced a quarterly cash dividend and an expanded authorization for its share repurchase program.
Baxter will present at the Raymond James & Associates 39th Annual Institutional Investors Conference on Tuesday, March 6, 2018, in Orlando, Fla. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 4:35 p.m. EST.
Baxter International, Inc. today reported results for the fourth quarter and full-year ended December 31, 2017, and provided its financial guidance for 2018.
Baxter announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin).
1/17/2018Despite some safety concerns such as severe diarrhea, the FDA approved Puma's breast cancer drug Nerlynx in July 2017.
Baxter Launches Arisure Closed System Transfer Device to Help Prevent Hazardous Drug Exposure and Maintain Medication Sterility
Baxter today announced a distribution agreement for the U.S. launch of the Arisure Closed System Transfer device.
Baxter will host a conference call to discuss its fourth quarter 2017 financial results on Thursday, February 1, 2018, at 7:30 a.m. Central Standard Time.
Baxter announced an agreement to acquire two hemostat and sealant products from Mallinckrodt plc: RECOTHROM Thrombin topical (Recombinant), the first and only stand-alone recombinant thrombin, and PREVELEAK Surgical Sealant, which is used in vascular reconstruction.
The dividend is payable on January 2, 2018, to stockholders of record as of December 1, 2017. The indicated annual dividend rate is $0.64 per share.